On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. Shares of Insulet were up by more than 2% on the news as of 2 p.m. EST. The integrated systems will allow patients to have their insulin delivery controlled automatically according to their blood glucose levels using disposable CGMs and Insulet's wearable, tubeless insulin delivery pods. The systems will use Insulet's Omnipod Horizon system, which it expects to launch in the second half of 2020. Image source: Getty Images. The increasing cooperation between Insulet and DexCom on an integrated system should come as little surprise, as the companies had already announced their partnership as part of Insulet's development program for Horizon, which is in a pivotal trial with up to 240 participants. Wednesday's press release announced a commercialization agreement between the companies, but the terms were not disclosed. The bigger news regarded the agreement with Abbott. The Horizon system was designed to work with multiple sensors, and although Abbott was the logical choice as a second partner, Insulet hadn't previously confirmed the companies were working on an integrated product. Abbott's FreeStyle Libre CGM is the market leader, and could be more important to Insulet's business than DexCom's devices. Core to the growth strategy of the rapidly expanding diabetes company is international expansion, and the massive Abbott already has 2 million FreeStyle Libre users in 46 countries. 10 stocks we like better than Abbott LaboratoriesWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy.Source